Prime Medicine, Inc.
NASDAQ:PRME · NASDAQ Global Market
-$0.04 today
Vol 3.19M · Avg 2.47M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-166.4%
avg -106.1%
ROIC
-66.5%
avg -72.7%
ROA
-58.7%
avg -50.1%
Analysis
ROA is currently the strongest return metric at -58.7% versus its period average of -50.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Allan Reine | Chief Executive Officer & Director | $1.07M | — | 51 | $1.30M | 0.72% |
Keith Michael Gottesdiener | Consultant | $1.02M | — | 72 | $75,000.00 | 0.04% |
Svetlana Makhni | Chief Financial Officer | $924,027.00 | — | 42 | $0.00 | <0.01% |
Ann L. Lee | Chief Technical Officer | $760,041.00 | — | 64 | $375,000.00 | 0.21% |
Jeffrey D. Marrazzo | Executive Chair | $140,161.00 | — | 47 | $75,000.00 | 0.04% |
Andrew Anzalone | Co-Founder | — | — | 39 | — | — |
David R. Liu | Co-Founder & Member of Scientific Advisory Board | — | — | — | $75,000.00 | 0.04% |
Mohammed Asmal | Chief Medical Officer | — | — | — | — | — |
Ryan E. Brown | Chief Legal Officer | — | — | 47 | — | — |
Niamh Alix | Chief Human Resources Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$35.05M
Sells
0
$0.00
Net Sentiment
+$35.05M
Net buying
Most Active
Liu David R.
2 transactions
Analysis
Insiders reported 6 buys worth $35.05M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $35.05M. Liu David R. was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.68B
Septerna, Inc.
NASDAQ:SEPN
$1.59B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.54B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.27B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.12B
Kura Oncology, Inc.
NASDAQ:KURA
$857.93M
Replimune Group, Inc.
NASDAQ:REPL
$836.46M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$729.83M
Rezolute, Inc.
NASDAQ:RZLT
$487.24M
ProKidney Corp.
NASDAQ:PROK
$261.51M
Who manages PRME?
Prime Medicine, Inc. (PRME) lists 10 active executives. The top listed executive is Allan Reine, Chief Executive Officer & Director.
Are PRME insiders buying or selling?
Recent insider activity shows net buying of $121.31M.
Explore More
Continue the stock analysis
Jump to another research area for this company.